Cardinal Health (CAH) is currently under Wall Streets focus due to varying outlooks and sector volatility. The company's stock has been fluctuating, even though market trends show an uptick. Revenue predictions indicate a decline by 2025, primarily due to the loss of the OptumRx contract. Looking forward, opportunities are now available for investing through options. The company's equity Rx program is expanding, which could potentially shape its future investment thesis. With a consistently growing product demand, CAH stock might rise before Q4 earnings. It's also important to note the upcoming earnings report. Analysts remain bullish about the Ohio-based company, but Q3 2025 results indicate a mixed impact on the stocks. Long-term growth has been affirmed, raising the company's outlook. Despite recent market gains, the Ohio-based company's stock has seen drops. Over the longer term, CAH is considered a strong momentum and value stock by investors. It also targets a double-digit EPS growth amid Individual Retirement Account (IRA) tailwinds and sector strength. The latest earnings missed revenue estimates but exceeded profit expectations amid tariff headwinds. Greater financial plans are set with a $10B cash flow plan that could boost its earnings forecast.
Cardinal Health CAH News Analytics from Sat, 02 Nov 2024 07:00:00 GMT to Sat, 09 Aug 2025 12:29:57 GMT -
Rating 2
- Innovation -2
- Information 7
- Rumor -3
